Disease	Advanced cancer/solid tumor only
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	More than 2 prior regimens
Type of Study	Phase I, modified continual reassessment method using a Bayesian logistic regression model with escalation with overdose control principle
Primary Endpoints	Maximum tolerated dose, recommended phase II dose
Secondary Endpoints	Pharmacodynamics, safety
Investigator’s Analysis	Due to dose-limiting skeletal muscle toxicities and the lack of efficacy at the maximum tolerated dose of 100 mg, further enrollment was stopped